Rhythm Pharmaceuticals Inc logo

Rhythm Pharmaceuticals Inc

NAS:RYTM (USA)  
$ 41.97 +0.175 (+0.42%) 10:11 AM EST
At Loss
P/B:
14.67
Volume:
67.26K
Avg Vol (2M):
610.85K
Also Trade In:
Volume:
67.26K
At Loss
Avg Vol (2M):
610.85K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for RYTM ( Rhythm Pharmaceuticals Inc ) from 2017 to Mar 28 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Rhythm Pharmaceuticals stock (RYTM) PE ratio as of Mar 28 2024 is 0. More Details

Rhythm Pharmaceuticals Inc (RYTM) PE Ratio (TTM) Chart

To

Rhythm Pharmaceuticals Inc (RYTM) PE Ratio (TTM) Historical Data

Total 1261
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Rhythm Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-03-28 At Loss 2024-01-24 At Loss
2024-03-27 At Loss 2024-01-23 At Loss
2024-03-26 At Loss 2024-01-22 At Loss
2024-03-25 At Loss 2024-01-19 At Loss
2024-03-22 At Loss 2024-01-18 At Loss
2024-03-21 At Loss 2024-01-17 At Loss
2024-03-20 At Loss 2024-01-16 At Loss
2024-03-19 At Loss 2024-01-12 At Loss
2024-03-18 At Loss 2024-01-11 At Loss
2024-03-15 At Loss 2024-01-10 At Loss
2024-03-14 At Loss 2024-01-09 At Loss
2024-03-13 At Loss 2024-01-08 At Loss
2024-03-12 At Loss 2024-01-05 At Loss
2024-03-11 At Loss 2024-01-04 At Loss
2024-03-08 At Loss 2024-01-03 At Loss
2024-03-07 At Loss 2024-01-02 At Loss
2024-03-06 At Loss 2023-12-29 At Loss
2024-03-05 At Loss 2023-12-28 At Loss
2024-03-04 At Loss 2023-12-27 At Loss
2024-03-01 At Loss 2023-12-26 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss
2024-02-22 At Loss 2023-12-15 At Loss
2024-02-21 At Loss 2023-12-14 At Loss
2024-02-20 At Loss 2023-12-13 At Loss
2024-02-16 At Loss 2023-12-12 At Loss
2024-02-15 At Loss 2023-12-11 At Loss
2024-02-14 At Loss 2023-12-08 At Loss
2024-02-13 At Loss 2023-12-07 At Loss
2024-02-12 At Loss 2023-12-06 At Loss
2024-02-09 At Loss 2023-12-05 At Loss
2024-02-08 At Loss 2023-12-04 At Loss
2024-02-07 At Loss 2023-12-01 At Loss
2024-02-06 At Loss 2023-11-30 At Loss
2024-02-05 At Loss 2023-11-29 At Loss
2024-02-02 At Loss 2023-11-28 At Loss
2024-02-01 At Loss 2023-11-27 At Loss
2024-01-31 At Loss 2023-11-24 At Loss
2024-01-30 At Loss 2023-11-22 At Loss
2024-01-29 At Loss 2023-11-21 At Loss
2024-01-26 At Loss 2023-11-20 At Loss
2024-01-25 At Loss 2023-11-17 At Loss

Rhythm Pharmaceuticals Inc (RYTM) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.